1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

Merck's Anacetrapib Survives Futility Exam, But Will It Pass Final Test?

 
• By Mandy Jackson

Merck & Co. Inc. has been fairly tight-lipped about its cholesteryl ester transfer protein (CETP) inhibitor anacetrapib for hypercholesterolemia while the 30,000-patient Phase III REVEAL clinical trial is ongoing, but the company said on Nov. 13 that the drug passed a recent futility test.

Merck & Co. Inc. has been fairly tight-lipped about its cholesteryl ester transfer protein (CETP) inhibitor anacetrapib for hypercholesterolemia while the 30,000-patient Phase III REVEAL clinical trial is ongoing, but the company said on Nov. 13 that the drug passed a recent futility test.

The REVEAL data monitoring committee (DMC) conducted a planned review of unblinded safety and efficacy data and said the trial...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapy Areas

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.